To propose a significant change in anti-angiogenic therapy by leveraging the DRD2/VEGF-A feedback loop for improved patient selection and treatment optimization.
Key Findings:
DRD2 activation selectively inhibits VEGFR2 phosphorylation and vascular permeability in tumor endothelium.
The VEGF-A–ERK1/2–KLF11 signaling axis serves as a biomarker for predicting responsiveness to DRD2 agonists.
DRD2 agonists can normalize vascular permeability without systemic toxicity.
Interpretation:
The proposed approach transforms anti-angiogenic therapy into a precision theranostic platform, allowing for real-time assessment of tumor VEGF-dependency and enhancing treatment efficacy.
Limitations:
The need for high-resolution spatial transcriptomic mapping is critical for precision stratification across diverse tumor microenvironments to ensure effective treatment.
Conclusion:
The study suggests that targeting the DRD2/VEGF-A feedback mechanism could enhance the efficacy and safety of anti-angiogenic treatments.
The ECOG-ACRIN Cancer Research Group, in collaboration with the SWOG Cancer Research Network, has launched a new initiative to analyze paired original and recurrent tumor specimens from two practice-c...
IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore how automation, AI, closed systems, and smarter supply chain models are helping advanced therapies move toward scalable delivery
